Alabama Department of Public Health
Alabama Emergency Response Technology (ALERT)
Health Alert Network (HAN)
January 24, 2025
UPDATE concerning any adverse reactions related to injectable ceftriaxone

ADPH, in collaboration with CDC and FDA, is continuing to review reports of any potential adverse events after injections of ceftriaxone that have occurred in the last few months in Alabama. ADPH does not have additional cases to add, at this time, but numbers may change after completion of record review with CDC and any additional reports through ADPH confidential provider link.

Key Messages:

1. At this time, no causal link between ceftriaxone and adverse events has been found, but ADPH is following its investigative procedures to determine whether there is a specific concern for ceftriaxone or other agents.
2. Providers should continue to use their clinical judgement regarding appropriate medical indications for use of ceftriaxone. Providers are urged to discuss the use of ceftriaxone with patients as a therapeutic and have a plan in place to respond to any adverse events.
3. No specific lot numbers or manufacturers of ceftriaxone have been determined to be potential causes of adverse reactions. ADPH is aware that some information about lot numbers and manufacturers has been provided on social media, but this information is not correct and did not come from ADPH investigation.
4. Providers should report potential adverse events related to ceftriaxone to ADPH at the link below:

https://redcap.link/AdverseEventReport2

Additionally, adverse events may be reported to FDA MEDWATCH:

https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program